Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced a multi-year strategic research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.